Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs
DNA methylation · human · 104 samples
- What it is
- DNA methylationChemical marks on DNA that help switch genes on or off.
- Organism
- Homo sapiens (human)
- Topic
- Myelodysplastic syndromesThis series is part of our curated briefing on it.
- Samples
- 104 samples: 26 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsNature communications · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE275000_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for beta-value tables or raw IDAT files among the supplementary files.
Also filed as BioProject PRJNA1148925 and SRA study SRP526818. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 52 samples.
How we read this: 26 replicated groups read from 104 sample titles; they account for 52 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8464115 P24_C1D1 P24_C1D
- GSM8464116 P24_C1D8 P24_C1D
- GSM8464117 P19_C1D1 P19_C1D
- GSM8464118 P19_C1D8 P19_C1D
- GSM8464119 P04_C1D1 P04_C1D
- GSM8464120 P04_C1D8 P04_C1D
- GSM8464121 P27_C1D1 P27_C1D
- GSM8464122 P27_C1D8 P27_C1D
- GSM8464123 P09_C1D1 P09_C1D
- GSM8464124 P09_C1D8 P09_C1D
- GSM8464125 P09_C7D1 P09_C7D
- GSM8464126 P09_C7D22 P09_C7D
- GSM8464127 P38_C1D1 P38_C1D
- GSM8464128 P38_C1D8 P38_C1D
- GSM8464129 P10_C1D1 P10_C1D
- GSM8464130 P10_C1D8 P10_C1D
- GSM8464131 P10_C7D1 P10_C7D
- GSM8464132 P10_C7D22 P10_C7D
- GSM8464133 P16_C1D1 P16_C1D
- GSM8464134 P16_C1D8 P16_C1D
- GSM8464135 P16_C7D1 P16_C7D
- GSM8464136 P16_C7D22 P16_C7D
- GSM8464137 P14_C1D1 P14_C1D
- GSM8464138 P14_C1D8 P14_C1D
- GSM8464139 P01_C1D1 P01_C1D
- GSM8464140 P01_C1D8 P01_C1D
- GSM8464141 P28_C1D1 P28_C1D
- GSM8464142 P28_C1D8 P28_C1D
- GSM8464143 P15_C1D1 P15_C1D
- GSM8464144 P15_C1D8 P15_C1D
- GSM8464145 P15_C7D1 P15_C7D
- GSM8464146 P15_C7D22 P15_C7D
- GSM8464147 P17_C1D1 P17_C1D
- GSM8464148 P17_C1D8 P17_C1D
- GSM8464149 P17_C7D1 P17_C7D
- GSM8464150 P17_C7D22 P17_C7D
- GSM8464151 P18_C1D1 P18_C1D
- GSM8464152 P18_C1D8 P18_C1D
- GSM8464153 P22_C1D1 P22_C1D
- GSM8464154 P22_C1D8 P22_C1D
+ 64 more — browse all 104 samples with per-sample file links →
- GSE298729 Chromatin accessibility of hematopoietic stem/progenitor cells (HSPCs) derived from MDS patients before and after disease progression 2 samples same disease briefing · shares mds, hspcs
- GSE284647 The genotype-integrated gene expression profile at the single-cell level of bone marrow CD34-positive hematopoietic stem and progenitor cells (HSPCs) from a patient with myelodysplastic neoplasms (MDS) harboring germline and somatic DDX41 variants. 1 samples same disease briefing · shares mds, hspcs
- GSE129828 DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of Myelodysplastic Syndromes 141 samples same disease briefing · shares methylation, distinct
- GSE264117 Investigating microenvironment in MDS II 503 samples same disease briefing · shares mds
- GSE298020 PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression. 493 samples same disease briefing · shares mds
- GSE281562 Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacytidine [RNA-Seq] 83 samples same disease briefing · shares mds
- GSE31174 Affymetrix SNP array data for myelodysplastic syndromes (MDS) and related neoplasms 58 samples same disease briefing · shares mds
- GSE326589 Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS 58 samples same disease briefing · shares mds
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.